Putative atherogenic factors in patients with chronic renal failure

Green, David; Stone, Neil J.; Krumlovsky, Frank A.

doi:10.1016/0033-0620(83)90027-0

Cited by 64 publications

(22 citation statements)

References 114 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The high mortality rate from atherosclerotic vascular disease is Cholesterol Metabolism in End-Stage Renal Disease 1081 well documented, although the specific risk factors or mechanisms which are responsible for this disease remain less clearly identified (5,6). There has been repeated documentation of abnormal triglyceride metabolism in ESRD patients, but the importance of this factor in the pathogenesis of atherosclerosis is controversial (10)(11)(12).…”

Section: Discussionmentioning

confidence: 99%

“…The final concentration of lecithin liposomes in the assay was 0.4 mg/ml. Plasma (1)(2)(3)(4)(5) (23,24). Plasma was diluted twofold with saline containing Tris and EDTA and brought to 1.5 mM 5,5'-dithiobis(2-nitrobenzoic acid), an inhibitor of plasma LCAT activity.…”

Section: Methodsmentioning

confidence: 99%

“…Patients with chronic renal insufficiency and end-stage renal disease (ESRD)' form an additional large group with a welldefined, high risk of vascular disease (5,6). This risk may or may not be accelerated by dialysis treatment per se (7,8).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

Dieplinger¹,

Schoenfeld²,

Fielding³

1986

J. Clin. Invest.

View full text Add to dashboard Cite

Plasma cholesterol metabolism was investigated in normotriglyceridemic patients with end-stage renal disease treated by hemo-or continuous ambulatory peritoneal dialysis (CAPD), and compared with that in a control group with normal renal function. A reversed net transport of free cholesterol from plasma to cultured fibroblasts, as well as greatly reduced levels of plasma cholesterol esterification and cholesterol ester transfer rates to low and very low density lipoproteins (LDL and VLDL), was found in the hemodialysis group compared to the controls. The LDL and VLDL contained increased amounts of free cholesterol and inhibited cholesterol ester transfer when recombined with control plasma. The LDL triglyceride content was doubled in the hemodialysis group, whereas cholesterol esters were decreased. Patients treated by CAPD, in marked contrast, had cholesterol metabolic rates that were within the normal range, as well as normal lipoprotein composition.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

Dieplinger¹,

Schoenfeld²,

Fielding³

1986

J. Clin. Invest.

View full text Add to dashboard Cite

show abstract

“…Disturbance in lipoproteins, is has been a feature of Chronic renal failure, along with cholesterol and triglycerides to be raised, and PUFAs to be lesser. All these abnormalities have been identified to be a sole risk factor for atherosclerosis, [12][13][14][15] with poor results with dialysis treatment. [16] An increased plasma homocysteine concentration is more among hemodialysis patients, [17,18] and also considered to be risk factor for atherosclerotic complications of ESRD.…”

Section: Introductionmentioning

confidence: 99%

To Analyse the Pattern of Lipid Profile in Patients of Chronic Kidney Disease

Verma¹,

Singh²

2018

AIMDR

View full text Add to dashboard Cite

Background: Chronic kidney disease (CKD), is a progressive and irreversible deterioration in the function of kidney over months to years,2 which is defined as"glomerular filtration rate (GFR) lesser than 60 ml/min with protenuria for 3 months".3 It leads to various biochemical disturbances and numerous clinical symptoms and signs.4Some of the associated changes are abnormalities in haematology parameters, heart related issues, disturbances of gastrointestinal tract, neurologic disorder, osteodystrophy, skin related problems and sexual dysfunction. Dyslipidemias are a common among CRF patients. The disturbances of lipoprotein metabolism are seen in early stages of CRF and can follow decrement pattern that follows the renal function deterioration. Aim and Objectives This study was aimed to analyse the pattern of lipid profile among the dif. Methods: The study was cross-sectional observational study conducted on 100 patients either attending or being admitted in the department of Internal Medicine, TMMC & RC, TMU , Moradabad, U.P., INDIA, which were in line with the inclusion criteria. Result & Conclusion: Our results indicated that patients undergoing CRF show important abnormalities of lipid metabolism which could contribute to atherosclerosis and cardiovascular disease and may increase the morbidity and mortality in these patients.

show abstract

“…Coronary heart disease (CHD) is an important cause of morbidity and mortality in patients with chronic renal disease – nephrotic syndrome and uraemia [1, 2, 3]. The high CHD prevalence in these patients is likely related to their high frequency of hyperlipidaemia [1, 2, 3].…”

Section: Introductionmentioning

confidence: 99%

Direct Method for the Measurement of Low-Density Lipoprotein Cholesterol Levels in Patients with Chronic Renal Disease: A Comparative Assessment

Akanji¹

1998

Nephron

View full text Add to dashboard Cite

Background/Aim: This study was performed to comparatively evaluate the results obtained for low-density lipoprotein (LDL) cholesterol concentrations by either a newly described direct method or the Friedewald equation in subjects with and without chronic renal disease. Methods: Fasting plasma was obtained from a total of 169 subjects, 105 with normal renal function (including 53 hyperlipidaemic) and 64 with chronic renal disease (nephrotic syndrome and/or chronic renal failure; including 40 hyperlipidaemic patients), and analyzed for LDL cholesterol using the Friedewald equation and a direct LDL assay method. Results: The Friedewald equation and the direct LDL cholesterol assay correlated well with each other (r = 0.79–0.90 in all subjects with plasma triglyceride, TG, levels greater than or less than 4.0 mmol/l and with and without chronic renal disease and/or hyperlipidaemia, all p < 0.0001). The values for LDL cholesterol, however, tended to be higher with the direct measurement. This mean difference was trivial in hyperlipidaemic subjects with (8.5%) and without (7.1%) normal renal function (both p < 0.05), but could be clinically significant in those with TG >4.0 mmol/l (mean difference 18%, p < 0.001). Indeed, bias plots confirmed this observation of wider negative bias for Friedewald estimation in these moderately hypertriglyceridaemic subjects. Conclusion: For most routine laboratories the options immediately available for assessment of lipid levels are the Friedewald equation or the direct measurement. The Friedewald equation and the direct assay method for LDL cholesterol are about equally good for assessment of the LDL status in patients with chronic renal disease and plasma TG <4.0 mmol/l. Where there are restraints on laboratory budgets, it would appear appropriate that the more expensive direct assay method be restricted to cases in whom plasma TG >4.0 mmol/l or to patients who, for whatever reason, are unable to produce fasting samples.

show abstract

Putative atherogenic factors in patients with chronic renal failure

Cited by 64 publications

References 114 publications

Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis.

To Analyse the Pattern of Lipid Profile in Patients of Chronic Kidney Disease

Direct Method for the Measurement of Low-Density Lipoprotein Cholesterol Levels in Patients with Chronic Renal Disease: A Comparative Assessment

Contact Info

Product

Resources

About